WO2009044883A1 - モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 - Google Patents

モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 Download PDF

Info

Publication number
WO2009044883A1
WO2009044883A1 PCT/JP2008/068092 JP2008068092W WO2009044883A1 WO 2009044883 A1 WO2009044883 A1 WO 2009044883A1 JP 2008068092 W JP2008068092 W JP 2008068092W WO 2009044883 A1 WO2009044883 A1 WO 2009044883A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
remedy
active ingredient
acid addition
addition salt
Prior art date
Application number
PCT/JP2008/068092
Other languages
English (en)
French (fr)
Inventor
Shinji Ona
Koichiro Takeshita
Naoki Ando
Masahiro Yamashita
Original Assignee
Toray Industries, Inc.
Torii Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc., Torii Pharmaceutical Co., Ltd. filed Critical Toray Industries, Inc.
Priority to TW097138034A priority Critical patent/TWI453020B/zh
Priority to AU2008308005A priority patent/AU2008308005B2/en
Priority to MX2010003660A priority patent/MX2010003660A/es
Priority to US12/680,908 priority patent/US20100222309A1/en
Priority to CN200880110176.5A priority patent/CN101848714B/zh
Priority to ES08835121T priority patent/ES2748274T3/es
Priority to PL08835121T priority patent/PL2196206T3/pl
Priority to EP08835121.8A priority patent/EP2196206B8/en
Priority to KR1020107007134A priority patent/KR101173509B1/ko
Priority to CA2702032A priority patent/CA2702032C/en
Priority to BRPI0817804A priority patent/BRPI0817804A8/pt
Priority to JP2009536121A priority patent/JP5613417B2/ja
Publication of WO2009044883A1 publication Critical patent/WO2009044883A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Abstract

　本発明は、様々な原因で起こる皮膚機能の低下に対して、皮膚の保湿効果を介して皮膚乾燥、肌荒れ、角質肥厚に伴うくすみ等の皮膚性状を改善する治療に有用な新規薬剤を提供することを目的とする。本発明は、下記の構造式（ＩＩ）で表される化合物１に代表される特定のモルヒナン骨格を有する化合物、またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬を提供するものである。
PCT/JP2008/068092 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 WO2009044883A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
TW097138034A TWI453020B (zh) 2007-10-05 2008-10-03 嗎啡喃衍生物或其藥理容許酸加成鹽之用以製造防止皮膚乾燥、改善肌膚粗糙、改善伴隨角質肥厚之發暗之改善治療藥之用途
AU2008308005A AU2008308005B2 (en) 2007-10-05 2008-10-03 Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
MX2010003660A MX2010003660A (es) 2007-10-05 2008-10-03 Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
US12/680,908 US20100222309A1 (en) 2007-10-05 2008-10-03 Skin property-improving therapeutic agent comprising a morphinan derivative or any of its pharmacologically permissible acid addition salts as an active ingredient
CN200880110176.5A CN101848714B (zh) 2007-10-05 2008-10-03 以吗啡喃衍生物或其药理学上允许的酸加成盐为有效成分的皮肤性状改善治疗药
ES08835121T ES2748274T3 (es) 2007-10-05 2008-10-03 Remedio para aliviar los problemas de la piel que comprende un derivado de morfinano o una sal de adición de ácido farmacológicamente aceptable del mismo como el principio activo
PL08835121T PL2196206T3 (pl) 2007-10-05 2008-10-03 Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
EP08835121.8A EP2196206B8 (en) 2007-10-05 2008-10-03 Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
KR1020107007134A KR101173509B1 (ko) 2007-10-05 2008-10-03 모르피난 유도체 또는 그 약리학적으로 허용되는 산부가염을 유효 성분으로 하는 피부 성상 개선 치료약
CA2702032A CA2702032C (en) 2007-10-05 2008-10-03 Skin property-improving therapeutic agent comprising a morphinan derivative or any of its pharmacologically permissible acid addition salts as an active ingredient
BRPI0817804A BRPI0817804A8 (pt) 2007-10-05 2008-10-03 Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
JP2009536121A JP5613417B2 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-262015 2007-10-05
JP2007262015 2007-10-05

Publications (1)

Publication Number Publication Date
WO2009044883A1 true WO2009044883A1 (ja) 2009-04-09

Family

ID=40526303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068092 WO2009044883A1 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬

Country Status (14)

Country Link
US (1) US20100222309A1 (ja)
EP (1) EP2196206B8 (ja)
JP (1) JP5613417B2 (ja)
KR (1) KR101173509B1 (ja)
CN (1) CN101848714B (ja)
AU (1) AU2008308005B2 (ja)
BR (1) BRPI0817804A8 (ja)
CA (1) CA2702032C (ja)
ES (1) ES2748274T3 (ja)
MX (1) MX2010003660A (ja)
PL (1) PL2196206T3 (ja)
RU (1) RU2440117C1 (ja)
TW (1) TWI453020B (ja)
WO (1) WO2009044883A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105475A1 (ja) 2011-01-31 2012-08-09 東レ株式会社 悪液質の治療又は予防剤
US11082591B2 (en) 2017-03-03 2021-08-03 Amazon Technologies, Inc. Solar-charging mounting bracket for audio/video recording and communication devices
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101732042B1 (ko) * 2010-01-29 2017-05-02 도레이 카부시키가이샤 담도 질환의 치료 또는 예방제
EP2630150B1 (en) * 2010-10-19 2017-04-12 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
ES2623262T3 (es) 2012-12-14 2017-07-10 Purdue Pharma Lp Derivados de morfinano que contienen nitrógeno y el uso de los mismos
CA2896202A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
EP3291676B1 (en) 2015-04-30 2022-08-17 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
US20210015813A1 (en) 2018-03-08 2021-01-21 Victoria Link Ltd. Treatment of demyelinating diseases
KR20230031207A (ko) * 2020-06-30 2023-03-07 도레이 카부시키가이샤 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204815A (ja) * 1989-07-10 1991-09-06 Baker Cummins Dermatologicals Inc 皮膚炎に対する治療用組成物
JPH05124930A (ja) 1990-07-25 1993-05-21 Takara Belmont Co Ltd 化粧料
WO1993015081A1 (fr) 1992-01-23 1993-08-05 Toray Industries, Inc. Derive de morphinane et utilisation en medicine
WO1995003307A1 (fr) 1993-07-19 1995-02-02 Toray Industries, Inc. Agent de protection de cellules cerebrales
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
WO1998023290A1 (fr) 1996-11-25 1998-06-04 Toray Industries, Inc. Agent antiprurigineux
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
WO1999005146A1 (fr) 1997-07-25 1999-02-04 Toray Industries, Inc. Remedes contre l'hyponatremie
WO1999011289A1 (fr) 1997-09-02 1999-03-11 Toray Industries, Inc. Remedes contre la toxicomanie
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
WO2001014383A1 (fr) 1999-08-24 2001-03-01 Toray Industries, Inc. Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques
WO2002078744A1 (fr) 2001-03-30 2002-10-10 Toray Industries, Inc. Remedes contre la psychonevrose
WO2002089845A1 (en) 2001-05-08 2002-11-14 Toray Industries, Inc. Remedies for sepsis
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
WO2004074277A1 (ja) * 2003-02-19 2004-09-02 Hisamitsu Medical Co., Ltd. Ｎ－アリール又はｎ－ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP2005220027A (ja) * 2004-02-03 2005-08-18 Ss Pharmaceut Co Ltd ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
WO2006095836A1 (ja) 2005-03-10 2006-09-14 Toray Industries, Inc. 多発性硬化症に伴う痒みに対する止痒剤
WO2007053194A2 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3843456B2 (ja) * 1993-07-23 2006-11-08 東レ株式会社 モルヒナン誘導体および医薬用途

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204815A (ja) * 1989-07-10 1991-09-06 Baker Cummins Dermatologicals Inc 皮膚炎に対する治療用組成物
JPH05124930A (ja) 1990-07-25 1993-05-21 Takara Belmont Co Ltd 化粧料
WO1993015081A1 (fr) 1992-01-23 1993-08-05 Toray Industries, Inc. Derive de morphinane et utilisation en medicine
JP2525552B2 (ja) 1992-01-23 1996-08-21 東レ株式会社 モルヒナン誘導体および医薬用途
WO1995003307A1 (fr) 1993-07-19 1995-02-02 Toray Industries, Inc. Agent de protection de cellules cerebrales
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
WO1998023290A1 (fr) 1996-11-25 1998-06-04 Toray Industries, Inc. Agent antiprurigineux
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
WO1999005146A1 (fr) 1997-07-25 1999-02-04 Toray Industries, Inc. Remedes contre l'hyponatremie
WO1999011289A1 (fr) 1997-09-02 1999-03-11 Toray Industries, Inc. Remedes contre la toxicomanie
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
WO2001014383A1 (fr) 1999-08-24 2001-03-01 Toray Industries, Inc. Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques
WO2002078744A1 (fr) 2001-03-30 2002-10-10 Toray Industries, Inc. Remedes contre la psychonevrose
WO2002089845A1 (en) 2001-05-08 2002-11-14 Toray Industries, Inc. Remedies for sepsis
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
WO2004074277A1 (ja) * 2003-02-19 2004-09-02 Hisamitsu Medical Co., Ltd. Ｎ－アリール又はｎ－ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP2005220027A (ja) * 2004-02-03 2005-08-18 Ss Pharmaceut Co Ltd ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
WO2006095836A1 (ja) 2005-03-10 2006-09-14 Toray Industries, Inc. 多発性硬化症に伴う痒みに対する止痒剤
WO2007053194A2 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Fundamentals and Clinical Practice of external Preparations for Eczema Dermatitis Group. Moisturizing Agents Used in Dermatological Regions (in Japanese)", JOURNAL OF JAPAN ORGANIZATION OF CLINICAL DERMATOLOGISTS, JAPAN ORGANIZATION OF CLINICAL DERMATOLOGISTS, vol. 56, April 1998 (1998-04-01), pages 87 - 96
AKIRA HATTORI ET AL.: "Rinsho Hifuka", vol. 44, January 1990, IGAKU-SHOINLTD., article "Skin Changes in Hemodialysis Patients", pages: 21 - 24
AKIRA HATTORI: "Cutaneous Lesions of Dialysis Patients. General Remarks", RINSHO TOSEKI, vol. 11, no. 13, October 1995 (1995-10-01), pages 1877 - 1881
AKIRA HATTORI: "Substances Relating to Complications Observed with Uremia and Chronic Dialysis X) Skin Disorders", RINSHO TOSEKI, vol. 21, no. 9, 10 August 2005 (2005-08-10), pages 1237 - 1242
B. FJELLNER: "Acta Dermato-venereologica. Supplementum", vol. 97, 1981, SCANDINAVIAN UNIVERSITY PRESS, article "Experimental and Clinical Pruritus. Studies on Some Putative Peripheral Mediators. The Influence of Ultraviolet Light and Transcutaneous Nerve Stimulation", pages: 1 - 34
BIOORG. MED. CHEM. LETT., vol. 5, 1995, pages 1505
CHEM. PHARM. BULL., vol. 52, 2004, pages 664
HEREROCYCLE, vol. 63, 2004, pages 865
HIDEO UMEUCHI ET AL.: "European Journal of Pharmacology, Netherlands", vol. 447, 2003, ELSEVIER SCIENCE, article "Involvement of Central µ-opioid System in the Scratching Behavior in Mice, and the Suppression of It by the Activation of K-opioid System", pages: 29 - 35
HIDEO UMEUCHI ET AL.: "Journal of Pharmacological Sciences", vol. 91, 1 March 2003, THE JAPANESE PHARMACOLOGICAL SOCIETY, article "Anti-Pruritic Effect of a Kappa Opioid Receptor Agonist TRK-820", pages: 198
HIRONARI KUMAGAYA ET AL.: "Itching up date: Effectiveness of K-opioid Agonists for Itching of Dialysis Patients", vol. 104, 25 August 2005, PUBLISHING ASSOCIATION OF ALL JAPANESE HOSPITALS, pages: 59 - 64
HIRONARI KUMAGAYA ET AL.: "Sogo Rinsho", vol. 53, 1 May 2004, NAGAI SHOTEN CO., LTD., article "Imbalance in Opioid System as a Cause of Uremic Pruritus and Effect of a Novel K-Agonist, TRK-820", pages: 1678 - 1684
IDIT F. SCHWARTZ ET AL.: "Nephrology, Dialysis, Transplantation, official publication of the European Dialysis and Transplant Association - European Renal Association", vol. 14, 1999, OXFORD UNIVERSITY PRESS, article "Uraemic Pruritus", pages: 834 - 839
KENJI TAKAMORI: "Rinsho Hifuka", vol. 56, 10 April 2002, IGAKU-SHOIN LTD., article "Opioid Peptide Targetting Treatment of Pruritus", pages: 145 - 147
MEI BIGLIARDI-QI ET AL.: "µ-opiate Receptor and Beta-endorphin Expression in Nerve Endings and Keratinocytes in Human Skin", DERMATOLOGY, vol. 209, no. 3, 2004, pages 183 - 189
MEI BIGLIARDI-QI ET AL.: "The Journal of Investigative Dermatology", vol. 114, March 2000, NATURE PUBLISHING GROUP, article "?-endorphin Stimulates Cytokeratin 16 Expression and Downregulates µ-opiate Receptor Expression in Human Epidermis", pages: 527 - 532
MIKA ADACHI ET AL.: "Fragrance Journal", vol. 33, 15 June 2005, FRAGRANCE JOURNAL LTD., article "New Role of ?-endorphin in Skin", pages: 35 - 38
See also references of EP2196206A4
SHIGEO KOCHI: "Rinsho Geka", vol. 56, 20 November 2001, IGAKU-SHOIN LTD., article "Knowledge of Diseases Common to Dermatology Necessary for Surgeons 6. Skin Pruritus and Mechanism of Itching", pages: 1522 - 1524
TAKAYUKI MIYAMOTO ET AL.: "Japanese Journal of Pharmacology", vol. 88, 1 March 2002, THE JAPANESE PHARMACOLOGICAL SOCIETY, article "Itch-associated Response Induced by Experimental Dry Skin in Mice", pages: 285 - 292
TATSUYA MAEKAWA ET AL.: "Japanese Journal of Pharmacology", vol. 90, 1 October 2002, THE JAPANESE PHARMACOLOGICAL SOCIETY, article "Effects of Naltrexone on Spontaneous Itch-associated Responses in NC Mice with Chronic Dermatitis", pages: 193 - 196
YUKIHIRO YADA ET AL.: "Purification and Biochemical Characterization of Membrane-bound Epidermal Ceramidases from Guinea Pig Skin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, USA, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 270, no. 21, 26 May 1995 (1995-05-26), pages 12677 - 12684, XP000937467

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105475A1 (ja) 2011-01-31 2012-08-09 東レ株式会社 悪液質の治療又は予防剤
US9006262B2 (en) 2011-01-31 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
US11082591B2 (en) 2017-03-03 2021-08-03 Amazon Technologies, Inc. Solar-charging mounting bracket for audio/video recording and communication devices
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US20100222309A1 (en) 2010-09-02
BRPI0817804A8 (pt) 2017-04-18
JP5613417B2 (ja) 2014-10-22
EP2196206B1 (en) 2019-07-17
MX2010003660A (es) 2010-08-10
EP2196206A1 (en) 2010-06-16
AU2008308005A1 (en) 2009-04-09
CN101848714B (zh) 2014-08-20
TW200927116A (en) 2009-07-01
CN101848714A (zh) 2010-09-29
EP2196206A4 (en) 2010-09-22
TWI453020B (zh) 2014-09-21
ES2748274T3 (es) 2020-03-16
BRPI0817804A2 (pt) 2016-10-11
AU2008308005B2 (en) 2012-06-07
EP2196206B8 (en) 2019-11-13
JPWO2009044883A1 (ja) 2011-02-10
KR101173509B1 (ko) 2012-08-14
KR20100049683A (ko) 2010-05-12
CA2702032A1 (en) 2009-04-09
CA2702032C (en) 2013-04-02
RU2440117C1 (ru) 2012-01-20
PL2196206T3 (pl) 2020-02-28

Similar Documents

Publication Publication Date Title
WO2009044883A1 (ja) モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬
WO2007002013A3 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
WO2008096841A1 (ja) 二量化シクロ誘導体
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011014588A3 (en) Dermal formulations of dp2 receptor antagonists
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2006113204A3 (en) Thymidine derivatives for treatmemt of kaposi's sarcoma
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
WO2009038412A3 (en) Beta-secretase inhibiting compounds
MY163762A (en) Therapeutic agent for chronic renal failure
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
WO2005112914A3 (en) Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
WO2004032873A3 (en) Therapeutic combination of carnitine and antioxidant polyphenols
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2008133297A1 (ja) ジスキネジアの治療または予防剤
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
WO2009148290A3 (en) 3-substituted propanamine compounds
WO2008099781A1 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
WO2009038411A3 (en) Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110176.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835121

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009536121

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12680908

Country of ref document: US

Ref document number: 2008308005

Country of ref document: AU

Ref document number: 2008835121

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107007134

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2702032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003660

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1289/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008308005

Country of ref document: AU

Date of ref document: 20081003

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010117649

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0817804

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100405